Monitoring of serum markers, including calcium, phosphate, PTH, vitamin D and alkaline phosphatase activity, as well as other diagnostic tools, are essential in the management of SHPT and CKD-MBD, and treatment decisions should be based on a combined assessment of these parameters [4]. The gene discussed is PTH; the disease is Marchiafava-Bignami disease.